首页 >
法规速递
-
Page: Biosimilar medicines: marketing authorisation-2025/2/19
2025-02-20查看详情 > -
Page: Artificial intelligence-2025/2/18
2025-02-19查看详情 > -
Page: Changing the labelling and package leaflet (Article 61(3) notifications)-2025/2/18
2025-02-19查看详情 > -
Page: Transfer of marketing authorisation: questions and answers-2025/2/18
2025-02-19查看详情 > -
Page: Type-II variations: questions and answers-2025/2/18
2025-02-19查看详情 > -
Page: Worksharing: questions and answers-2025/2/18
2025-02-19查看详情 > -
Page: Type-IB variations: questions and answers-2025/2/18
2025-02-19查看详情 > -
Document: Checklist for the submission of Type IA and Type IB (without linguistic review) product information annexes and Annex A (if applicable) - human-2025/2/18
2025-02-19查看详情 > -
Document: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with track changes-2025/2/18
2025-02-19查看详情 > -
Document: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure-2025/2/18
2025-02-19查看详情 >